GW Pharma owns Epidiolex the world’s most popular cannabis based medicine.
GW pharma is a global leader in discovering, developing, manufacturing and commercializing novel, regulatory approved therapeutics from its proprietary cannabinoid product platform to address a broad range of diseases.
The proposed transaction would be the largest move to date by a pharma company into cannabis and the combined company will be a leader in neuroscience with a global commercial and operational footprint well positioned to maximize the value of its diversified portfolio.
Jazz Pharmaceuticals acquiring GW Pharma in this $7.2 Billion deal, will gain control of Epidiolex, the cannabis-based medicine used to treat severe types of epilepsy in children.
Epidiolex was approved by the US FDA in 2018 after extensive clinical trials and was the first approved cannabis-based medicine which only contained CBD.
The medicine has been approved for use in the U.S, most of Europe and Australia. Total sales reached US$526 million in 2020 and according to Prohibition Partners’ forecast, sales will reach US$940m by the end of this year.
This deal represents the continuation of a trend which has seen an increasing number of pharmaceutical heavyweights enter the cannabis industry such as Novartis, Sanofi and Teva Pharmaceuticals.
Compared to Sativex and Dronabinol, Epidiolex will see the fastest rate of sales and represent the biggest share of the market over the next four years.
This acquisition indicates the increased interest of investors in companies producing medical cannabis products. The cannabis market is offering more and more opportunities for investors that they want to take the next step to enter in the medical cannabis industry.
Greece is one of the top European destinations for investments in medical cannabis cultivation, processing and distribution for those who want to enter in the medical cannabis market.
VK PREMIUM offers an enhanced palette of consulting services to facilitate medical cannabis investments in Greece, including strategy & planning, products portfolio as of current & future market trends, licensing, grants utilizing Investment Incentive Law, design & construction of the facility in accordance with EU GMP & GACP standards and distribution strategies to secure sales success in foreign markets.
Call us at : +30 2106835560, send email to : info[@]vkmedicalcannabis.com or fill the bellow form: